Rare diseases
Investigational molecules
Locations
324 No 88 Meiliang Road, Mashan Street, Binhu District, 214091
D3 Bio (Wuxi) Co. Ltd. focuses on clinical research in advanced solid tumors, with attention to cancers carrying a KRAS p.G12C mutation. Its trial activity is centered on adult oncology populations with molecularly defined disease.
The sponsor’s research interest is concentrated on targeted cancer treatment for mutation-driven malignancies, including both single-agent and combination approaches within solid tumor care.
D3 Bio (Wuxi) Co. Ltd. runs clinical trials in conditions such as Neoplasm, among others.
Clinical trials run by this sponsor – those enrolling participants first.
FranceIncrease visibility for your trials and help patients find your site through our platform.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
